Skip to Content

A New Vaccine Against Multiple Sclerosis

Initial human tests show the vaccine appears safe and triggers beneficial changes in the brain.
August 14, 2007

An experimental DNA vaccine against multiple sclerosis (MS) appears safe in early human tests and shows signs of effectiveness, according to a paper published Monday in the online version of the Archives of Neurology.

In MS, the immune system attacks the fatty coating, known as myelin, protecting nerve cells in the brain and spinal cord, eventually destroying nerve cells’ ability to communicate. The cause of the disease is unknown.

In the study, headed by Amit Bar-Or of the Montreal Neurological Institute in Canada, patients were given a vaccine made up of one of the protein components of myelin. The idea is that the vaccine will damp the body’s tendency to attack myelin.

While larger studies are needed to determine if the vaccine will truly help MS patients, initial results were promising. The vaccine appears safe and showed early signs of a beneficial effect on the immune system: the number of immune cells in the spinal fluid that attack myelin was reduced in a small subset of patients who underwent lumbar puncture. A larger study of the vaccine is now under way.

Keep Reading

Most Popular

Geoffrey Hinton tells us why he’s now scared of the tech he helped build

“I have suddenly switched my views on whether these things are going to be more intelligent than us.”

Meet the people who use Notion to plan their whole lives

The workplace tool’s appeal extends far beyond organizing work projects. Many users find it’s just as useful for managing their free time.

Learning to code isn’t enough

Historically, learn-to-code efforts have provided opportunities for the few, but new efforts are aiming to be inclusive.

Deep learning pioneer Geoffrey Hinton has quit Google

Hinton will be speaking at EmTech Digital on Wednesday.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.